Gland Pharma Q1 FY26 YoY PAT up by 50% to Rs. 216 Cr

Cenexi reports an EBITDA breakeven for the quarter

Roche’s Susvimo maintains vision over five years

Strides Pharma Science report Q1 FY26 PAT at Rs. 105.6 Cr

EBITDA rose to Rs. 218.1 crore, a 14.8% year-on-year increase

Johnson & Johnson submits additional data to FDA on psoriatic arthritis

The submission is supported by results from the Phase 3b APEX study

GlaxoSmithKline Pharmaceuticals reports Q1 FY26 PAT at Rs. 205 Cr

The performance was below anticipated levels, primarily due to external factors such as seasonal disruption that affected overall results

JB Pharma Q1 FY26 PAT up at 14% to Rs. 202 Cr

Sun Pharmaceutical Q1 FY26 consolidated PAT falls by 20% to Rs. 2,278 Cr

India Formulation sales accounted for 34.2% of total consolidated sales for the quarter

USPTO issues final rejection of Rampart IC's radiation shield patent claims

The request stemmed from a 2024 lawsuit by Rampart alleging Egg Medical had infringed its patent

Bliss GVS Pharma posts Q1 FY26 PAT higher at Rs. 43.03 Cr

Bliss GVS Pharma has reported total income of Rs. 242.92 crores during the period ended June 30, 2025

Zydus completes acquisition of 85.6% stake in Amplitude Surgical